KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue: 2014-2024

Historic Non-Current Deffered Revenue for Aurinia Pharmaceuticals (AUPH) over the last 4 years, with Dec 2024 value amounting to $1.7 million.

  • Aurinia Pharmaceuticals' Non-Current Deffered Revenue was N/A to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is N/A change from last year.
  • Aurinia Pharmaceuticals' Non-Current Deffered Revenue amounted to $1.7 million in FY2024, which was up 724.76% from $206,000 recorded in FY2019.
  • Aurinia Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $1.7 million during FY2024, with a 5-year trough of $1.7 million in FY2024.
  • Its 1-year average for Non-Current Deffered Revenue is $1.7 million, with a median of $1.7 million in 2024.